Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | SUITE 619, 855 N. WOLFE STREET BALTIMORE MD 21205 |
Tel: | N/A |
Website: | https://championsoncology.com |
IR: | See website |
Key People | ||
Brady Davis President | Ronnie Morris Chief Executive Officer, Director | David Miller Chief Financial Officer |
Business Overview |
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company's TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets. |
Financial Overview |
For the nine months ended 31 January 2024, Champions Oncology Inc revenues decreased 11% to $36.2M. Net loss increased from $2.8M to $7.2M. Revenues reflect Pharmacology services segment decrease of 71% to $11.2M, Other segment decrease of 64% to $835K. Higher net loss reflects general and administratiojn increase of 10% to $7.8M (expense), Sales and marketing - Balancing value increase of 2% to $5.1M (expense). |
Employees: | 230 as of Jul 15, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $62.69M as of Jan 31, 2024 |
Annual revenue (TTM): | $49.22M as of Jan 31, 2024 |
EBITDA (TTM): | -$6.81M as of Jan 31, 2024 |
Net annual income (TTM): | -$9.73M as of Jan 31, 2024 |
Free cash flow (TTM): | -$6.72M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 13,593,766 as of Jan 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |